Exosome Surface Modification & Targeting Engineering

Q: Do you offer targeting validation?

Yes. We offer in vivo biodistribution and tumor accumulation studies using fluorescently labeled surface-engineered vesicles. Targeting performance is quantified by target-to-liver ratio, tumor accumulation fold-enhancement over unmodified vesicles, and competitive inhibition confirmation in vivo. These studies are available as integrated packages or standalone validation services.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide comprehensive surface modification and targeting engineering services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), cytoplasmic membrane vesicles (CMVs; also referred to as membrane vesicles, MVs) from Gram-positive bacteria, fungal EVs, and phage-infected bacterial vesicles. Our platform integrates genetic surface display of targeting ligands and antigens, chemical conjugation of functional moieties, stealth coating and circulation enhancement, targeted cellular uptake validation, and surface characterization into a single, integrated workflow that transforms native microbial vesicles into precision-targeted nanocarriers and vaccine platforms.

Unlike generic nanocarrier engineering CROs that apply liposome or polymeric nanoparticle surface chemistry to microbial vesicles without adaptation, we have developed surface modification strategies specifically calibrated for the unique lipid composition, membrane protein landscape, and surface charge properties of microbial vesicles. From genetic fusion construct design to validated targeting performance, clients receive surface-engineered vesicle batches with quantified ligand display density, confirmed targeting specificity, and improved therapeutic index that support vaccine development, targeted drug delivery, and diagnostic imaging applications. Contact us to discuss your surface engineering and targeting requirements.

Scientific schematic of integrated surface modification and targeting engineering platform for microbial extracellular vesicles, showing genetic surface display, chemical conjugation, stealth coating, targeted uptake validation, and surface characterization modules arranged around a central engineered vesicle particle.
Figure 1. Schematic overview of the integrated surface modification and targeting engineering platform for microbial extracellular vesicles, spanning genetic surface display, chemical conjugation, stealth coating, targeted cellular uptake validation, and surface characterization.

Services

Service Workflow

Commercial end-to-end service workflow diagram for surface modification and targeting engineering showing seven stages from project inquiry through surface strategy design, genetic or chemical modification, display validation, stealth optimization, uptake confirmation, and final engineered vesicle delivery with characterization report.

Inquiry

Service Details

Biological cross-section illustration showing a bacterial cell expressing plasmid-encoded surface-display fusion proteins, with targeting ligands and antigens presented on the outer membrane and packaged into budding vesicles during biogenesis.

Genetic Surface Display & Ligand Engineering

We engineer microbial strains to genetically fuse targeting ligands, antigens, or functional peptides to vesicle membrane proteins, enabling direct surface display on nascent vesicles during biogenesis. Our capabilities include anchor protein selection for OMV and CMV platforms, fusion construct design with secretion signal optimization, plasmid-based and chromosomal integration strategies, and multi-ligand co-display using orthogonal tagging systems. Displayed moieties evaluated include tumor-homing peptides, antibody fragments, vaccine antigens, and immune adjuvant proteins. Clients receive genetically stable production strains and surface-engineered vesicles with validated ligand display density and confirmed functional activity on the vesicle surface.

Molecular close-up illustration showing a microbial vesicle surface with chemical conjugation sites highlighted, functional ligands attached via linker chemistry, and surface charge modification indicators visible on the membrane.

Chemical Surface Conjugation & Functionalization

We chemically modify purified mEV surfaces to attach targeting ligands, fluorescent reporters, and functional moieties post-isolation. Our capabilities include amine- and sulfhydryl-reactive conjugation chemistry, lipid insertion of functionalized phospholipids, click-chemistry-based site-specific labeling, and surface charge modulation. Functional modifications span cell-penetrating peptides for enhanced internalization, folate and mannose ligands for receptor-targeted delivery, near-infrared dyes for imaging, and biotin-streptavidin bridging for modular ligand attachment, with assessment of LPS layer integrity post-modification for OMV substrates. Clients receive chemically modified vesicles with quantified surface ligand density, preserved membrane integrity, and validated functional activity compared to unmodified controls.

Split-screen comparison showing unmodified microbial vesicles on the left being rapidly cleared by immune recognition, and PEGylated stealth vesicles on the right with prolonged circulation and reduced immune clearance.

Stealth Coating & Circulation Enhancement

We modify mEV surfaces with stealth coatings that reduce immune recognition, prolong circulation half-life, and enhance accumulation at target tissues. Our capabilities include polyethylene glycol (PEG) insertion via lipid anchors, zwitterionic polymer coating for reduced protein corona formation, and charge-neutralizing surface modifications. Stealth performance is evaluated by serum protein adsorption profiling, macrophage uptake reduction assays, and circulation persistence in vivo, with coating density optimized to preserve desired immunogenicity while enhancing circulation. Formulation optimization includes cryoprotectant screening and lyophilization cycle development to maintain stealth coating integrity during storage. Clients receive stealth-coated vesicles with demonstrated circulation enhancement and reduced reticuloendothelial system clearance.

Process flow illustration showing engineered vesicles with targeting ligands approaching specific cell types, followed by receptor-mediated binding, enhanced internalization, and intracellular trafficking visualized in a step-by-step sequence.

Targeted Cellular Uptake Validation

We validate the targeting specificity and uptake efficiency of surface-engineered mEVs against target and non-target cell populations. Our capabilities include competitive binding assays with free ligand inhibition, receptor-blocking confirmation using antagonist antibodies, uptake kinetics across multiple cell lines, and co-localization studies with endosomal and lysosomal markers. Target cell panels span tumor cells, macrophages, dendritic cells, intestinal epithelial cells, and skin keratinocytes. Uptake enhancement is quantified as fold-increase over unmodified vesicles with statistical significance testing. Clients receive comprehensive uptake validation reports with receptor specificity confirmation, dose-dependent internalization curves, and mechanism-of-entry profiling.

Abstract data visualization showing a surface characterization dashboard with zeta potential shifts, display efficiency bar charts, ligand density heatmaps, and comparative surface property analysis between modified and unmodified vesicles.

Surface Characterization & Display Efficiency Quantification

We comprehensively characterize the physicochemical and biochemical surface properties of modified mEVs to ensure modification quality and batch consistency. Our capabilities include surface charge and hydrophobicity profiling, ligand display density quantification by nano-flow cytometry and biosensor-based ligand binding characterization, membrane integrity assessment before and after modification, and batch-to-batch surface property consistency monitoring. Display efficiency is reported as ligand molecules per vesicle, percentage of vesicles displaying at least one ligand, and surface coverage density. Clients receive surface characterization reports with modification confirmation data, quality control metrics, and batch consistency matrices suitable for CMC documentation and regulatory submissions.

Service Specifications & QC Standards

Instrumentation & Capability

Genetic Engineering: CRISPR-based genome editing and recombination systems for endogenous surface display strain development.
Nano-Flow Cytometry: High-sensitivity flow cytometry optimized for nanoparticle analysis, for surface ligand display quantification and targeted cellular uptake validation.
Surface Plasmon Resonance: Label-free biosensor systems for ligand-receptor binding affinity determination.
Dynamic Light Scattering & Zeta Potential: Surface charge and hydrodynamic size analysis before and after modification.
Confocal Microscopy: High-resolution imaging for uptake co-localization and intracellular trafficking visualization.
In Vivo Imaging: Whole-body fluorescent and bioluminescent imaging for targeted biodistribution validation.
Western Blot & ELISA: Immunodetection systems for surface protein display confirmation and ligand quantification.

Typical Data Range

Genetic display efficiency: 10²–10⁴ ligands per vesicle (anchor dependent).
Chemical conjugation density: 10³–10⁵ ligands per vesicle (chemistry dependent).
PEGylation efficiency: >70% vesicle surface coverage with PEG chains.
Targeted uptake enhancement: 2–10-fold increase over unmodified vesicles (ligand and cell type dependent).
Stealth coating circulation extension: 2–5-fold increase in half-life vs. unmodified vesicles.
Surface charge shift upon modification: 10–40 mV change in zeta potential.
Batch-to-batch display density CV: <20% for qualified surface engineering protocols.

Turnaround Time

Project Type	Timeline
Genetic surface display strain construction	4–6 weeks
Chemical conjugation protocol development	2–3 weeks
Stealth coating optimization	2–4 weeks
Targeted uptake validation (single cell type)	2–3 weeks
Surface characterization package	1–2 weeks
In vivo targeting validation (single model)	4–6 weeks
Integrated targeting engineering package	8–12 weeks
Expedited timeline	+50% fee, 40% time reduction

Timeline may vary based on ligand complexity, modification strategy, and validation scope.

Deliverables

Genetic display report: Construct maps, expression validation, display density quantification, strain stability data.
Chemical conjugation report: Ligand density, surface charge shifts, membrane integrity, functional activity confirmation.
Stealth coating report: Protein corona reduction, macrophage uptake suppression, circulation half-life data.
Targeted uptake report: Uptake enhancement fold-change, receptor specificity confirmation, dose-response curves.
Surface characterization report: Zeta potential, display efficiency, batch consistency matrices, QC documentation.
In vivo targeting report: Biodistribution imaging, target-to-liver ratio, tumor accumulation data (if applicable).

Quality Control

Pre-modification baseline: NTA, DLS, zeta potential, and protein content on every batch before modification.
Post-modification QC: Size, polydispersity, surface charge, and endotoxin level after surface engineering.
Ligand display validation: Flow cytometry or SPR confirmation of surface ligand presence on modified vesicles.
Unmodified control: Every experiment includes unmodified vesicle control for direct comparison.
Intra-assay CV ≤ 15%; inter-assay CV ≤ 20% for all quantitative surface characterization endpoints.
Compliance checklist for minimal characterization requirements aligned with industry guidelines for extracellular vesicle studies.

Sample Requirements

Required Information	Optional Information	Not Accepted
Ligand or antigen sequence/structure for display Target cell type or tissue for validation mEV type (OMVs, CMVs, fungal EVs, phage-infected bacterial vesicles) Purified vesicle suspension with NTA concentration Modification strategy preference (genetic vs. chemical) Intended application (vaccine, drug delivery, imaging)	Prior surface modification data or literature Specific receptor or target molecule of interest Desired display density or ligand copy number Stealth or circulation enhancement requirements Competitive ligand or antagonist for specificity testing Regulatory documentation needs	Ligands with documented membrane-disrupting activity Uncharacterized or aggregation-prone protein ligands Samples with endotoxin >10 EU/mg protein (stricter limits may apply depending on intended application) Radioactive or biohazardous ligands without permits Intact bacterial or fungal cell cultures Samples shipped without cold-chain documentation

Recommended Sample Quantity by Service:

Service	Minimum Volume	Recommended Volume
Genetic display strain construction	N/A (strain generated in-house)	Gene sequence or expression plasmid
Chemical conjugation	200 μL	500 μL
Stealth coating	300 μL	600 μL
Targeted uptake validation	200 μL	400 μL
Surface characterization	100 μL	200 μL
In vivo targeting validation	500 μL	1 mL (volume scales with study design and animal model)

Storage & Shipping: Ship purified vesicle suspensions on dry ice (–80°C) with cold-chain documentation. Ligands should be shipped according to their specific stability requirements. Provide sequence information, certificate of analysis, and safety data sheet for the ligand. For genetic display projects, provide the expression construct or gene sequence with restriction map.

Inquiry

Our Advantages

mEV-Specific Surface Chemistry: Our genetic and chemical modification strategies are specifically designed for microbial vesicle surfaces, accounting for their unique lipopolysaccharide composition, outer-membrane protein landscape, and surface charge properties that differ fundamentally from mammalian exosomes or synthetic liposomes.
Dual Modification Platform: We offer both genetic surface display (stable, heritable, scalable production) and chemical conjugation (rapid, flexible, post-isolation modification), enabling clients to select the optimal approach based on ligand properties, development timeline, and manufacturing requirements.
Validated Targeting Performance: Our targeted uptake validation services confirm receptor specificity through competitive inhibition and receptor-blocking assays, ensuring that observed uptake enhancement is ligand-dependent and not artifactual.
Plug-and-Display Multi-Antigen Capability: Our orthogonal tagging systems enable simultaneous display of multiple ligands or antigens on a single vesicle surface, supporting complex vaccine platforms and multi-targeted drug delivery applications.
Regulatory-Ready Surface Documentation: Surface characterization reports include modification confirmation, display density quantification, batch consistency matrices, and QC documentation prepared in formats suitable for CMC packages and regulatory submissions.

Applications

Central focus composition with an OMV particle displaying multiple tumor antigens on its surface, surrounded by activated dendritic cells and cytotoxic T cells in an immune response context.

OMV Vaccine Antigen Display Platform

Genetic surface display of tumor or pathogen antigens on OMVs enables modular vaccine platform development.

Left-to-right narrative flow showing targeted ligand-decorated vesicles approaching tumor tissue, binding to cancer cell receptors, and delivering therapeutic cargo with enhanced specificity.

Tumor-Targeted Drug Delivery Nanocarrier

Surface targeting ligands direct drug-loaded vesicles to tumor cells with improved therapeutic index.

Split-screen comparison showing rapid clearance of unmodified vesicles versus prolonged circulation and enhanced tissue accumulation of PEGylated stealth vesicles.

Stealth mEV Circulation Enhancement

PEGylation and stealth coatings prolong circulation half-life and reduce immune clearance for therapeutic mEVs.

Scale transition from whole-body imaging showing fluorescent vesicle biodistribution down to tissue-level probe accumulation for diagnostic imaging applications.

Imaging-Probe Functionalized mEV Diagnostics

Fluorescent or radiolabeled surface modifications enable mEV tracking and diagnostic imaging.

Case Study

Case Study: Plug-and-Display Bioengineered OMVs as a Versatile Tumor Vaccine Platform

Researchers developed a bioengineered outer membrane vesicle (OMV) tumor vaccine platform using plug-and-display technology. SpyCatcher and SnoopCatcher were genetically fused to ClyA for surface display on OMVs (ClyA-Catcher, CC OMVs), enabling rapid, modular attachment of SpyTag- or SnoopTag-labeled tumor antigens onto the same OMV surface via isopeptide bond formation without reconstructing the production strain for each antigen.

The multi-antigen OMV vaccines activated dendritic cell maturation and induced antigen-specific T cell responses. In B16-OVA melanoma lung metastasis and MC38 subcutaneous colorectal cancer models, CC-SpT-Adpgk OMVs achieved 70% survival and 60% complete tumor regression by day 50, outperforming mixture formulations. The platform also induced long-term immune memory upon re-challenge, with 50% of mice resisting B16-OVA tumor rechallenge and 37.5% resisting B16-F10 rechallenge on day 60. This study demonstrates how genetic surface display combined with modular covalent tag-catcher coupling transforms bacterial OMVs into a flexible multi-antigen vaccine platform for cancer immunotherapy.

Figure 2. Dual-tumor antigen (OVA_257–264 and OVA_223–339) display by catcher-decorated OMVs triggers CD4⁺ and CD8⁺ T-cell-mediated synthetic anti-tumor immunity. (Cheng, et al. 2021)

FAQs

Q: What types of ligands can be displayed on microbial vesicle surfaces?

A: We have successfully displayed peptides (tumor-homing, cell-penetrating), antibody fragments (scFv, nanobodies), full-length proteins (vaccine antigens, immune adjuvants), aptamers, small-molecule ligands (folate, mannose), and fluorescent dyes on bacterial OMVs, probiotic CMVs, and fungal EVs. Ligand selection depends on molecular size, stability, and the intended targeting application.

Q: What is the difference between genetic and chemical surface modification?

A: Genetic modification fuses the ligand to a vesicle membrane protein during biogenesis, producing self-displaying strains ideal for large-scale manufacturing. Chemical modification attaches ligands to purified vesicles post-isolation, offering rapid turnaround and flexibility for screening multiple ligands without strain engineering. Many projects benefit from a hybrid approach: genetic display of a stable anchor with chemical conjugation of modular ligands.

Q: How many ligands can be displayed on a single vesicle?

A: Display density depends on the modification strategy and anchor protein. Genetic display typically achieves 10²–10⁴ ligands per vesicle (anchor dependent). Chemical conjugation can achieve 10³–10⁵ ligands per vesicle (chemistry dependent). Using orthogonal tagging systems such as SpyTag/SpyCatcher, we can simultaneously display two or more distinct ligands on the same vesicle surface for multi-targeting or multi-antigen vaccine applications.

Q: Can stealth coating reduce the immunogenicity of bacterial OMVs?

A: Yes. PEGylation and zwitterionic polymer coatings can reduce macrophage recognition and complement activation of bacterial OMVs, extending circulation half-life 2–5-fold. However, stealth coating may also mask surface-displayed targeting ligands or vaccine antigens. We optimize the coating density to balance circulation enhancement with preserved surface functionality.

Q: How do you confirm that uptake enhancement is truly ligand-specific?

A: We employ three orthogonal specificity controls: (1) competitive inhibition with excess free ligand to block receptor binding; (2) receptor-blocking using antagonist antibodies against the target receptor; (3) uptake comparison on receptor-negative cell lines. Only when uptake enhancement is abolished by all three controls do we confirm ligand-dependent targeting.

Q: Can surface-engineered vesicles be lyophilized for long-term storage?

A: Yes, with formulation optimization. Surface modifications—particularly PEG coatings and genetic fusion proteins—can be sensitive to freeze-thaw and lyophilization stress. We screen cryoprotectants (trehalose, sucrose) and optimize lyophilization cycles to maintain both vesicle integrity and surface ligand activity after reconstitution. Stability data is provided as part of the formulation package.

Q: Do you offer in vivo targeting validation?

A: Yes. We offer in vivo biodistribution and tumor accumulation studies using fluorescently labeled surface-engineered vesicles. Targeting performance is quantified by target-to-liver ratio, tumor accumulation fold-enhancement over unmodified vesicles, and competitive inhibition confirmation in vivo. These studies are available as integrated packages or standalone validation services.

Q: Can I provide my own ligand for surface display?

A: Absolutely. We accept client-provided ligands including purified proteins, synthetic peptides, small molecules, and antibodies. For genetic display, we require the DNA sequence or expression construct. For chemical conjugation, we require the ligand in a reactive or functionalized form (amine, sulfhydryl, or click-chemistry handle). We also offer ligand sourcing and synthesis through partner vendors if needed.

References:

Cheng, K., et al. (2021). Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nature Communications, 12, 2041.

Services

Inquiry